- Home
- STTK vs COEP Comparison
STTK vs COEP Comparison
Compare STTK & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- COEP
- Stock Information
- Founded
- STTK 2016
- COEP 2017
- Country
- STTK United States
- COEP United States
- Employees
- STTK N/A
- COEP N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STTK Health Care
- COEP Health Care
- Exchange
- STTK Nasdaq
- COEP Nasdaq
- Market Cap
- STTK 36.2M
- COEP 30.5M
- IPO Year
- STTK 2020
- COEP N/A
- Fundamental
- Price
- STTK $0.84
- COEP $11.68
- Analyst Decision
- STTK Hold
- COEP
- Analyst Count
- STTK 4
- COEP 0
- Target Price
- STTK $3.00
- COEP N/A
- AVG Volume (30 Days)
- STTK 305.5K
- COEP 25.5K
- Earning Date
- STTK 05-01-2025
- COEP 05-09-2025
- Dividend Yield
- STTK N/A
- COEP N/A
- EPS Growth
- STTK N/A
- COEP N/A
- EPS
- STTK N/A
- COEP N/A
- Revenue
- STTK $5,721,000.00
- COEP N/A
- Revenue This Year
- STTK N/A
- COEP N/A
- Revenue Next Year
- STTK N/A
- COEP N/A
- P/E Ratio
- STTK N/A
- COEP N/A
- Revenue Growth
- STTK 245.26
- COEP N/A
- 52 Week Low
- STTK $0.69
- COEP $2.31
- 52 Week High
- STTK $11.76
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- STTK 44.82
- COEP 69.07
- Support Level
- STTK $0.73
- COEP $9.16
- Resistance Level
- STTK $0.90
- COEP $11.69
- Average True Range (ATR)
- STTK 0.15
- COEP 0.48
- MACD
- STTK 0.00
- COEP 0.30
- Stochastic Oscillator
- STTK 19.96
- COEP 96.64
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.